Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 9, 2021

Rhea-AI Summary

Tricida, Inc. (TCDA) will report its Q2 2021 financial results on August 9, 2021. Following the release, a conference call and webcast will be held at 4:30 pm ET to discuss the results and business progress. The company focuses on developing veverimer, which addresses chronic metabolic acidosis in CKD patients, impacting an estimated three million individuals in the U.S. This condition currently lacks FDA-approved treatments.

Investors can access the call via dial-in or through their website.

SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2021 financial results after the close of market on Monday, August 9, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows:

Tricida Conference Call Information

Tricida will host its Second Quarter Financial Results and Business Update Conference Call and webcast on Monday August 9, 2021 at 4:30 pm Eastern Time. The webcast and slide presentation or conference call may be accessed as follows:

	Tricida Conference Call
	Monday, August 9, 2021
	4:30 pm Eastern Time
Webcast:		IR.Tricida.com
Dial-In:		(877) 377-5478
International:		(629) 228-0740
Conference ID:		9679330

A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis and slow CKD progression in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. There are no FDA-approved treatments for chronic metabolic acidosis. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.Tricida.com.

Contact:
Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

Source: Tricida, Inc.

FAQ

When will Tricida report its Q2 2021 financial results?

Tricida will report its Q2 2021 financial results on August 9, 2021.

What time is Tricida's conference call for Q2 2021 results?

The conference call will be held at 4:30 pm ET on August 9, 2021.

How can I access Tricida's Q2 2021 financial results conference call?

The call can be accessed via dial-in at (877) 377-5478 or through the webcast on their website.

What is Tricida's main drug candidate?

Tricida's main drug candidate is veverimer, designed to treat chronic metabolic acidosis in CKD patients.

How many patients in the U.S. are affected by chronic metabolic acidosis?

Chronic metabolic acidosis affects approximately three million patients with CKD in the United States.